RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help
doctors predict whether patients undergoing donor stem cell transplant will develop acute
PURPOSE: This clinical trial is studying T cells to see how well they help in predicting
acute graft-versus-host disease in patients undergoing donor stem cell transplant.
- To determine the association between regulatory T-lymphocyte (Treg) subsets present at
engraftment and at day 28 with the incidence of acute graft-versus-host-disease (aGVHD)
in patients undergoing allogeneic stem cell transplantation.
- To identify gut-homing and skin-homing Treg subsets and determine their role during
engraftment and at day 28 as a predictor of gut and skin aGVHD, respectively.
OUTLINE: Patients undergo blood sample collection at the time of neutrophil engraftment
prior to stem cell transplant (SCT) and post-SCT on days 7, 14, 21, and 28 days after
allogeneic stem cell transplantation. Blood samples are analyzed for T-cell subsets and for
the percentage of regulatory T-lymphocyte (Treg) or other T-cell subsets expressing specific
homing receptors for the gut or skin via flow cytometry.
Patients' medical records are also reviewed periodically.
- Patients undergoing allogeneic SCT
- Age >= 18 years
- Inability to give informed consent
- Patients who have not received an allogeneic SCT
- Any condition which, in the opinion of the investigator, might interfere with study
- Any reason which, in the opinion of the investigator, adds additional risk to the